Apellis Pharmaceuticals, Inc.

APLS

US03753U1060

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
47.93 ^USD	-4.01%		+0.88%	-19.93%

Apr. 17	Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	MT
Apr. 09	Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	MT

Apellis Pharmaceuticals : Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

January 08, 2020 at 08:31 am EST

WALTHAM - Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced positive results from the Phase 3 PEGASUS study evaluating pegcetacoplan (APL-2) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Top-line data show that pegcetacoplan met the study's primary efficacy endpoint, demonstrating superiority to eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p

Latest news about Apellis Pharmaceuticals, Inc.

Wedbush Cuts Price Target on Apellis Pharmaceuticals to $57 From $67, Keeps Neutral Rating	Apr. 17	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $3,743,605, According to a Recent SEC Filing	Apr. 09	MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 23rd Annual Needham Virtual Healthcare Conference, Apr-08-2024 12:45 PM	Apr. 08
Apellis Pharmaceuticals Insider Sold Shares Worth $1,068,161, According to a Recent SEC Filing	Mar. 21	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $564,050, According to a Recent SEC Filing	Mar. 20	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $645,838, According to a Recent SEC Filing	Mar. 14	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $4,297,549, According to a Recent SEC Filing	Mar. 11	MT
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024	Mar. 11	CI
JPMorgan Adjusts Price Target on Apellis Pharmaceuticals to $79 From $78, Maintains Overweight Rating	Mar. 06	MT
Apellis Pharmaceuticals Insider Sold Shares Worth $16,028,706, According to a Recent SEC Filing	Mar. 05	MT
Transcript : Apellis Pharmaceuticals, Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:00 AM	Mar. 05
Transcript : Apellis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-03-2024 through Mar-06-2024	Mar. 04
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	Mar. 04	MT
UBS Raises Apellis Pharmaceuticals Price Target to $89 From $87, Maintains Buy Rating	Mar. 04	MT
Wedbush Raises Apellis Pharmaceuticals' PT to $67 From $60, Keeps Neutral Rating; Says Awaiting Further Clarity on Potential EU Regulatory Path for Syfovre	Feb. 28	MT
Transcript : Apellis Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Apellis Pharmaceuticals' Q4 Net Loss Narrows, Revenue Increases	Feb. 27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Earnings Flash (APLS) APELLIS PHARMACEUTICALS Reports Q4 Revenue $146.4M	Feb. 27	MT
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
North American Morning Briefing : Stock Futures Pause as Investors Eye Inflation Data	Feb. 27	DJ
Mizuho Raises PT on Apellis Pharmaceuticals to $60 From $49 Ahead of Q4 2023 Earnings Announcement, Keeps Neutral Rating	Feb. 15	MT
UBS Adjusts Apellis Pharmaceuticals Price Target to $87 From $70, Maintains Buy Rating	Feb. 13	MT
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Jefferies Upgrades Apellis Pharmaceuticals to Buy From Hold, Adjusts Price Target to $80 From $68	Feb. 05	MT

Chart Apellis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Companyâs approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Apellis Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.93 USD

Average target price

82.01 USD

Spread / Average Target

+71.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
APELLIS PHARMACEUTICALS, INC.	-19.93%	5.78B
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-21.76%	29.48B
UCB	+55.51%	25.43B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	15.59B
INCYTE CORPORATION	-18.49%	11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+4.49%	8.75B

Biopharmaceuticals

Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Pharmaceuticals

Apellis Pharmaceuticals : Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

EPS Revisions